Quote:
Originally Posted by David Sklansky
Still with all these technical problems, I am left with these thoughts.
The lung cancer news guarantees no competitors.
There is a billionaire's reputation partly at stake.
Though people often lie with statistics, even dummies will realize that a "500% increase in lung cancer cases" is a misleading headline.
We are not talking about a drug company whose stock drops to two because their main drug is probably ineffective or perhaps very dangerous. It is my understanding that this product definitely works.
Besides working, it apparantly works better and to many is more desirable than the present alternatives. Except for the fact that there is possibly a three percent chance of complications. There is also a good chance that three percent is an overstatement, especially for non smokers. In any case if this company's product is the ONLY way to get the more desirable type of relief I would think many might take that three percent chance if it was stated on the label. And if it is stated on the label that protects them legally. I'm thinking that the FDA takes stuff like this into account. Its not like banning a pain pill for side effects when there are virtually equal, but safer products, out there.
Is there anything innacurate in the above words?
You've highlighted the optimistic spin on the positive factors. Others here have presented negative factors. You need to talk to an analyst who has dug into the details of this product to find out how accurate some of your above impressions are. However, when all is said what makes you believe these factors were not properly priced into the $6-2 drop when the Lung Cancer report came out? Surely they are all well known to the market.
Evidently all you have to go on is a hunch that the 66% drop is too extreme. This despite the lower probability of ever getting the product approved, the higher cost to a company that will be running out of money for getting it approved, the loss of interest by manufacturing partners, and the greater difficulty in developing a market which could not be developed by Pfizer despite a $2.8 billion effort, and was abandoned by Eli Lily with similiar products.
Maybe you're right. Get a hunch and bet a bunch. But how can you know? What makes you believe the market is not pricing these factors in better than you are doing? If this were a situation where you could do some fundamental analysis to support your hunch you would at least have something to go on. But that's not part of your investment strategy.
PairTheBoard